Dr. David Kyle to speak at the Microbiome R&D and Business Collaboration Congress: Asia
Davis, California Feb 23, 2016 – Evolve BioSystems, Inc., a mid-stage microbiome company developing the next generation of products to establish, restore, and maintain a healthy human gut microbiome, is pleased to announce that Evolve CEO, Dr. David Kyle, will be presenting at the 3rd Microbiome R&D and Business Collaboration Congress: Asia, which will be held on March 1 – 2, 2017 in Hong Kong.
The conference will bring together Pharma, Biotech, Academic Institutions and investors who are partnering together to develop and progress ground-breaking microbiome research into commercially viable products.
Dr. Kyle will be speaking in a special Solution Provider Presentation section of the program, providing valuable insights into the critical role of the infant gut microbiome in his talk titled, “The Infant Gut Microbiome: From Dysbiosis to Recovery.”
For more details on the Microbiome R&D and Business Collaboration Congress: Asia, please visit: http://www.global-engage.com/event/microbiome-asia/#speakers
To learn more about Evolve BioSystems, visit: www.evolvebiosystems.com
Tracy Shafizadeh, PhD
Director, Scientific Communications
About Evolve BioSystems
Evolve BioSystems, Inc. is a privately-held microbiome company dedicated to developing the next generation of products to establish, restore, and maintain a healthy human gut microbiome. Evolve is a spin-out from the Foods for Health Institute (FFHI) at the University of California, Davis and builds on more than a decade of research into understanding the unique partnership of the infant gut microbiome and breast milk components. Having led to the discovery and development of products to resolve infant gut dysbiosis, Evolve’s discovery platform is now being applied to solving gut dysbiosis throughout the human life cycle as well as in various animal species. Evolve completed a $9 million Series A capital raise in 2015 and has now successfully completed a milestone proof-of-concept study to demonstrate the efficacy of its initial proprietary offering. In addition, Evolve is undertaking further clinical studies to build out its offering of microbiome-based solutions across a spectrum of unmet clinical needs.